Christopher A.
- Country
- Austria
- Department
- N/A- private practice
Research Overview
- Effect of Muvalaplin on Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: A Phase 3 Randomized Trial
- Inclisiran for Prevention of Major Adverse Cardiovascular Events in High-Risk Primary Prevention Patients with Atherosclerotic Cardiovascular Disease
- Phase 3 Randomized Study Comparing Asundexian and Apixaban for Stroke Prevention in Atrial Fibrillation Patients at Risk
Data & Insights
Has run more than one trial at 772 of 1472 partner sites.
Specializations
Cardiovascular Prevention
Specializes in innovative approaches to primary prevention of atherosclerotic cardiovascular disease and management of cardiovascular risk factors.
- Major adverse cardiovascular events prevention
- Stroke prevention in atrial fibrillation
- Systemic embolism management
Focuses on preventive cardiology strategies for high-risk patients.
Cardiac and Vascular Conditions
Investigates advanced treatments for chronic heart failure and calcific aortic valve stenosis.
- Heart failure with reduced ejection fraction
- Aortic valve calcium progression
- Cardiac event prevention
Explores innovative therapeutic approaches for structural heart conditions.
Metabolic and Renal Disease
Conducts research in chronic kidney disease and type 2 diabetes mellitus management.
- Albuminuria reduction strategies
- Diabetic cardiovascular complications
- Renal function preservation
Addresses the intersection of metabolic disorders and cardiovascular health.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.